These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11479390)

  • 1. Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
    Micallef J; Blin O
    Clin Neuropharmacol; 2001; 24(4):191-207. PubMed ID: 11479390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for obsessive-compulsive disorder.
    Greist JH; Jefferson JW
    Br J Psychiatry Suppl; 1998; (35):64-70. PubMed ID: 9829028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.
    Shanahan NA; Velez LP; Masten VL; Dulawa SC
    Biol Psychiatry; 2011 Dec; 70(11):1039-48. PubMed ID: 21920503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.
    Denys D
    Psychiatr Clin North Am; 2006 Jun; 29(2):553-84, xi. PubMed ID: 16650723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsessive-compulsive disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Apr; 27(2):116-30. PubMed ID: 24576790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatry of obsessive-compulsive disorder in children and adolescents.
    March JS; Leonard HL; Swedo SE
    Compr Ther; 1995 Sep; 21(9):507-12. PubMed ID: 8565438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour.
    Wood J; LaPalombara Z; Ahmari SE
    Philos Trans R Soc Lond B Biol Sci; 2018 Mar; 373(1742):. PubMed ID: 29352023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible role of neuropeptides in obsessive compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Price LH
    Psychoneuroendocrinology; 1999 Jan; 24(1):1-24. PubMed ID: 10098217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.